Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an …
…, N Katakami, M Takada, H Yoshioka, K Shibata… - The lancet …, 2010 - thelancet.com
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00 …
…, T Yonei, K Nakano, M Tsuboi, K Shibata… - European journal of …, 2009 - Elsevier
We examined the impact of pretreatment neutrophil count on survival in patients with advanced
non-small-cell lung cancer (NSCLC). A total of 388 chemo-naïve patients with stage IIIB …
non-small-cell lung cancer (NSCLC). A total of 388 chemo-naïve patients with stage IIIB …
Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients
G Yasuda, K Shibata, T Takizawa, Y Ikeda… - American journal of …, 2002 - Elsevier
Many hemodialysis patients suffer from constipation. The frequency of constipation has not
been rigorously evaluated in continuous ambulatory peritoneal dialysis (CAPD) patients, …
been rigorously evaluated in continuous ambulatory peritoneal dialysis (CAPD) patients, …
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for …
…, N Katakami, M Takada, H Yoshioka, K Shibata… - 2012 - ascopubs.org
7521 Background: WJTOG3405 met its primary endpoint of progression free survival (PFS) (9.2
months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence interval (…
months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence interval (…
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for …
…, K Asami, N Katakami, M Takada, K Shibata… - 2014 - ascopubs.org
8117 Background: WJTOG3405 has proven that chemotherapy-naïve patients with
postoperative recurrent or stage IIIB/IV NSCLC harboring activating EGFRmutation have longer …
postoperative recurrent or stage IIIB/IV NSCLC harboring activating EGFRmutation have longer …
Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy
Y Makino, H Hosoda, K Shibata, I Makino, M Kojima… - …, 2002 - Am Heart Assoc
Ghrelin, an endogenous ligand for the growth hormone secretagogues, was originally isolated
from rat stomach. It stimulates the release of growth hormone from primary pituitary cell …
from rat stomach. It stimulates the release of growth hormone from primary pituitary cell …
Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal …
IKU OKAMOTO, M ABE, K SHIBATA… - American journal of …, 2000 - atsjournals.org
We studied the role of inducible nitric oxide synthase (iNOS) in septic lung injury using a
novel and selective iNOS inhibitor (a fused piperidine derivative; ONO-1714) following a cecal …
novel and selective iNOS inhibitor (a fused piperidine derivative; ONO-1714) following a cecal …
Regulation of ghrelin secretion during pregnancy and lactation in the rat: possible involvement of hypothalamus
K Shibata, H Hosoda, M Kojima, K Kangawa, Y Makino… - Peptides, 2004 - Elsevier
We investigated the plasma concentration of ghrelin peptide during pregnancy and lactation
in rats. Plasma ghrelin levels on days 10 and 15 of pregnancy were significantly lower than …
in rats. Plasma ghrelin levels on days 10 and 15 of pregnancy were significantly lower than …
[HTML][HTML] EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non–small cell lung cancer
H Kimura, K Kasahara, K Shibata, T Sone… - Journal of Thoracic …, 2006 - Elsevier
Background The authors evaluate the efficacy and safety of gefitinib monotherapy in
chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC). A secondary …
chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC). A secondary …
Real-world efficacy of first-line pembrolizumab in patients with advanced or recurrent non–small-cell lung cancer and high PD-L1 tumor expression
Y Tambo, T Sone, K Shibata, K Nishi, H Shirasaki… - Clinical Lung Cancer, 2020 - Elsevier
Background In clinical trials, first-line treatment with pembrolizumab improved overall survival
(OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a programmed …
(OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a programmed …